Flow Neuroscience

Flow Neuroscience is a healthcare company based in Malmö, Sweden, offering a non-invasive at-home treatment for depression. Their core product is the Flow tDCS (transcranial direct current stimulation) headset, which delivers gentle electrical currents to stimulate the left dorsolateral prefrontal cortex, an area of the brain associated with depression. This brain stimulation technique aims to restore activity in this region and alleviate depressive symptoms.

The Flow headset is designed to be used in conjunction with an app-based therapy program. The app provides personalized behavioral therapy, including mood tracking, self-help techniques, and educational content on the importance of factors like sleep, exercise, and nutrition in managing depression.

Flow Neuroscience's treatment approach combines decades of research in neuroscience and psychology with advanced technology. The company claims impressive results from clinical trials, with over 50% of participants achieving remission from depressive symptoms within 10 weeks of using the Flow headset.

In July 2022, Flow received FDA Breakthrough Device Designation, recognizing its innovative nature and potential advantages over existing treatments. The company has already obtained regulatory approval in Europe, and its headset is currently available over the counter in the UK and other European markets.

Flow Neuroscience's mission is to provide an effective, safe, and accessible treatment option for depression, enabling individuals to manage their condition conveniently from home with minimal side effects.

Key customers and partnerships

Flow Neuroscience has established partnerships with various healthcare providers and organizations, including the NHS (National Health Service) in the UK. The company has collaborated with the University of Texas and the University of East London to conduct clinical trials for its tDCS headset.

Additionally, Flow Neuroscience has partnered with Curebase, a company specializing in decentralized clinical trials, to conduct a remote study involving 270 participants in London and Houston. This collaboration aimed to evaluate the effectiveness of Flow's at-home headset in reducing depressive symptoms.

The company has also entered into a partnership with the General Practice Alliance (GPA), consisting of 21 GP practices in the UK. Under this partnership, Flow Neuroscience's headset will be trialed as an alternative or complementary treatment option for depression, alongside antidepressants and psychotherapy. This trial will be independently evaluated by the Research & Innovation Team at Northamptonshire healthcare NHS Foundation Trust (NHFT).